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Abstract 
A major challenge in matrix-metalloproteinase (MMP) target validation and MMP-inhibitor-drug 
development for anti-cancer clinical trials is to better understand their complex roles (often competing with 
each other) in tumor progression.  While there is extensive research on the growth-promoting effects of 
MMPs, the growth-inhibiting effects of MMPs has not been investigated thoroughly. So we develop a 
continuum model of tumor growth and invasion including chemotaxis and haptotaxis in order to examine 
the complex interaction between the tumor and its host microenvironment and to explore the inhibiting 
influence of the gradients of soluble fragments of extracellular matrix (ECM) density on tumor growth and 
morphology. Previously, it was shown both computationally (in one spatial dimension) and experimentally 
that the chemotactic pull due to soluble ECM gradients is anti-invasive, contrary to the traditional view of 
the role of chemotaxis in malignant invasion [1]. With two-dimensional numerical simulation and using a 
level set based tumor-host interface capturing method, we examine the effects of chemotaxis on the 
progression and morphology of a tumor growing in nutrient-rich and nutrient-poor microenvironments 
which was not investigated before. In particular we examine how the geometry of the growing tumor is 
affected when placed in different environments. We also investigate the effects of varying ECM degradation 
rate, the production rate of matrix degrading enzymes (MDE), and the conversion of ECM into soluble 
ECM. We find that chemotaxis due to ECM-fragment gradients strongly influences tumor growth and 
morphology, and that the instabilities caused by tumor cell proliferation and haptotactic movements can be 
prevented if chemotaxis is sufficiently strong. The influence of chemotaxis and the above factors on tumor 
growth and morphology are found to be more prominent in nutrient-poor environments than in nutrient-
rich environments. So we extend our investigations of these antinvasive chemotactic influences by 
examining the effects of cell-cell and cell-ECM adhesion and low proliferation rate for tumors growing in 
low-nutrient environments. We find that as the extent of chemotaxis increases, the effects of adhesion on 
tumor growth and shape become negligible. Under conditions of low cell mitosis, chemotaxis may cause 
the tumor to shrink, as the extent of chemotaxis increases. Both stable and unstable tumor shrinkage are 
predicted by our model. Unexpectedly, in some cases chemotaxis may contribute toward developing 
instability where haptotaxis alone induces stable growth. 
 
1. Introduction 
  
Cell motility, coupled with cell proliferation and regulated adhesion to the extracellular matrix (ECM), 
and degradation of ECM molecules, allows an invading tumor cell to move through the surrounding tissue 
[2, 3]. The ECM, a substantial component of tissue, consists of an interlocking mesh of fibrous proteins and 
polysaccharide including collagen, elastin, laminin, fibronectin and hyaluronan. ECM acts as a supporting 
structure to which cells can anchor and generate force. The state of macromolecules within the ECM is of 
critical importance and proteolysis is a major factor leading to changes in the ECM [4]. Cancer invasion 
involves the over-expression of proteolytic matrix degrading enzymes (MDEs), such as the urokinase-type 
plasminogen activator (uPA) and matrix metalloproteinases (MMPs). Although overexpression of MMPs 
correlate with poor prognosis in cancer patients, pharmaceutical inhibitors of MMP have failed clinically 
[5-9].  The reasons for failure can be the broad-spectrum activity of the inhibitors used, using inhibitors 
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during the latter stage of cancer, the opposite effects (pro-invasive and anti- invasive) exerted by MMPs on 
cancer progression [10] and altered signaling activities exhibited by MMPs during tumorigenesis [7]. The 
failure from the clinical trials has shed light on the diverse proteolytic activities involved during different 
steps of tumor progression and paved the way to explore underappreciated functions of proteases. The major 
challenge is to differentiate the action of MMPs that promote tumor growth and invasion from those that 
are crucial for host defense, as blocking the latter will worsen the clinical outcome [7]. 
A variety of soluble and substratum-bound factors influence directed cell migration at different stages 
during tumor invasion and metastasis. Haptotaxis is the directional motility of cells, usually up gradients of 
cellular adhesion sites in the ECM created through the degradation of the ECM by MDEs secreted by tumor 
cells. Chemotaxis is defined as cellular locomotion directed in response to a gradient of a soluble chemical 
factor. During the process of tumor invasion, proteolytic degradation also results in solubilisation of ECM 
components [11, 12] which induce chemotactic movement due to the gradients of soluble ECM fragments. 
Perumpanani et al. [1] showed that in the human fibrosarcoma cell line HT1080, MMP-2-digested 
fragments of fibronectin exert a chemotactic pull stronger than that of intact fibronectin.  As the gradient in 
degraded fragments is opposite to that of the direction of invasion, the chemotaxis due to these soluble 
fragments actually inhibits invasion. Thus, an optimally invasive phenotype corresponds to a balance 
between MMP production and inhibition, and the relative proportions of digested and intact ECM 
components. Therefore the therapeutic use of MMP inhibitors (MMPIs) against tumors expressing high 
levels of MMP could produce an augmentation of invasion. Klominek et al. [13] reported that  ECM 
proteins with molecular weight greater than 220,000 has both chemotactic and haptotactic properties, while 
the proteins with molecular weights of approximately 67,000 have chemotactic and chemokinetic (random 
motility) but not haptotactic properties. The importance of both pro- and anti-invasive properties of various 
proteases in cancer, which, depending on the circumstances, may either suppress or promote tumor growth 
are discussed in [8, 10, 14-16]. Nonetheless, the mechanisms by which these proteases exert their pro- or 
anti-invasive properties are largely unknown and represent a challenging issue for the near future [10]. 
Mathematical modeling has the potential to provide insight into tumor growth and invasion through 
systematic studies of fundamental constituent processes [17] and thereby reducing the number of costly 
experiments needed for the development of therapies. The effects of nutrient concentration (in the 
microenvironment) on shape instabilities of tumor growth has been investigated using level set methods 
[17-22].  Instability provides a mechanism for tumor invasion that does not require development of a 
neovasculature to supply essential nutrients. Poplawski et al. [23, 24] demonstrated that the development 
of instability depends primarily on the diffusional limitation parameter (ratio of tumor growth rate to 
diffusion rate of nutrients) while the morphological details depend on cell–cell adhesion. The lack of 
competition for nutrients (high nutrient environment) promotes spherical, noninvasive tumors. Low 
concentrations of nutrients (which cause tumor-cell competition), or cells with a very high nutrient-
consumption rate generate a fingering instability and irregular, invasive tumors. Their results agree with 
the in vitro and in vivo experiments conducted in [3, 25-27] and with other tumor-models predictions 
without considering haptotaxis [17, 20, 21, 28-30] and with haptotaxis [31-33]. Simulation results show 
that increases in both MDE secretion rate and the haptotaxis coefficient promote invasion [34] and 
inhibiting haptotaxis or the proteolysis result in less disperse invasion fronts [35] which is found in vitro  
case as well.  
 
Anticancer therapies are divided into two broad classes: antiproliferative (chemotherapy) and anti-
invasive therapy. Chemotherapy uses cytotoxic drugs to either slow down or block the cell division cycle 
causing cell death by attacking rapidly growing cells. Two chemotherapy protocols are used:  (i) a series of 
scheduled doses administered into the blood stream (free drug delivery) or (ii) releasing a drug at a constant 
rate through nanoparticles [36].  The Mathematical model based on first principles of cell biophysics, drug 
pharmaco-kinetics and drug pharmaco-dynamics developed by Pascal et al. [37] suggests that a continuous 
infusion of nanocarrier-mediated drug is more effective than scheduled doses because of the higher uptake 
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rate and hence lower amounts of drug are required to kill the same amount of cells due to improved cellular 
uptake rates.  The time-dependent model [37] is extended in [38] by accounting for spatial dependence in 
order to predict tumor response to different kinds of drug delivery methods (nano-vectored drug and free 
drug delivery).  Model predictions are also validated using experiments on an in vivo breast cancer mouse 
model with different drug delivery methods.  By combining  mathematical modeling with experiments in 
mice for predicting chemotherapy drug response, Frieboes et al. [39] showed that the drug response in mice 
(represented by the fraction of dead tumor volume) can be predicted from drug transport characteristics 
(blood volume fraction, average geometric mean blood vessel radius, drug diffusion penetration distance, 
and drug response  cell culture). Koay et al. [40] developed a mass transport model for measuring mass 
transport properties to describe qualities of the pancreatic tissue and its surrounding vasculature during 
routine contrast-enhanced CT scans of human pancreatic ductal adenocarcinoma (PDAC).   This clinical 
study based on discrete radiographic features of the PDAC showed that high stromal density inhibits 
incorporation of drug mediated by hENT1 (human equilibrative nucleoside transporter 1) into the tumor. 
The mechanistic model based on the physical laws of diffusion in [41] can accurately predict the fraction 
of tumor cells killed from chemotherapy in patients with glioblastoma  and colorectal cancer metastatic to 
liver based on parameter values that are measurable in clinical test.  
  
Regarding anti-invasive therapies, it was shown in [42] that in the presence of gradients of both soluble 
and fixed ECM gradients, inhibiting only haptotaxis could be inefficient. Berry et al. [43] presented a kinetic 
model that describes the interactions between ECM proteins, proteinases, proteolytic fragments, and 
integrins and focused on the role of the cryptic functions displayed by the proteolytic fragments of ECM in 
cell invasion. Another molecular-level model developed by this group is based on ECM remodeling using 
the kinetics of a proteinase/transglutaminase cycle interconverting insoluble ECM and soluble proteolysis 
fragments [44]. However the chemotaxis due to soluble fragments were not considered in those models [43, 
44]. Hacker [45] presented a mathematical model for the interactions of cells with ECM fiber network 
where metastatic tumor cells move due to anisotropic diffusion, haptotaxis (due to the gradients of 
undissolved adhesion sites in the ECM network) and chemotaxis (due to the solute network fragments, 
produced from proteolysis, and the epidermal growth factor which may guide the cells to a blood vessel).  
Numerical simulations were carried out in two space dimensions for different ratios of diffusive and 
chemotactic strength with and without haptotaxis. However this study assumed that tumor cells are neither 
proliferating nor apoptotic, so the effects of nutrient concentration were not included in the model.  
 
To date, no experimental or computational work has elucidated the motility retarding effects of digested 
fragments of ECM on tumor growth and morphology including cell proliferation and the effects of nutrient 
concentration in the microenvironment. Because these chemotactic gradients are soluble they would 
eventually be dissipated, resulting in continued invasion, although at a lower rate [1].  Our hypothesis is 
that the tumor morphology will change significantly due to the cell migration towards the chemotactic pull 
associated with the gradients of soluble fibronectin fragments. So we model tumor growth and invasion due 
to directed cell motion and investigate the role of chemotaxis and related biophysical parameters on tumor 
growth and morphology with the variations of nutrient availabilities in the microenvironment. In our model, 
cell motion depends on oncotic pressure from cell proliferation, adhesion forces between cells and between 
cells and the ECM, the relative strength of chemotaxis and haptotaxis due to the gradients of soluble ECM 
and insoluble ECM, respectively.  Using two-dimensional numerical simulations, we present the results of 
a parameter study of quantitative aspects of the tumor progression, such as the size and shape of tumors 
with a range of biophysical and chemotaxis parameters, and investigate the causal link between these 
parameters on tumor growth and morphology. Our study stands out from previous mathematical 
investigations in the following ways: 
 
(i) While earlier mathematical models have examined the enhancement effect of MMP (by 
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haptotaxis) on tumor growth and morphology; our model is the first to investigate the inhibitory 
effects of MMP (by chemotaxis) with variations of nutrient concentrations in the 
microenvironment (nutrient-rich and nutrient-poor microenvironments).  
(ii) We include tumor-cell motion due to cell-proliferation (primary source of cell movement) and 
cell-cell and cell-ECM adhesion pressure in our chemotaxis model, not included earlier. 
(iii) We investigate the influence of chemotaxis due to soluble-ECM gradients, for tumors growing in 
hypoxic environments with varying extents of cell adhesion 
(iv) The influences of chemotaxis and haptotaxis on tumor growth dynamics and morphology under 
conditions of low cell proliferation in a low-nutrient environment are investigated here.  
 
The various influences of fragments of ECM through chemotaxis on tumor growth and 
morphology predicted by our study, might partially explain why the MDE inhibitors have not been 
successful as therapeutic agents in clinical trials. Especially, we show that the tumor morphology 
is unstable with increase in ECM degradation rate if the chemotaxis coefficient is not strong 
enough and chemotaxis may contribute to the initiation of the instability for low proliferation 
environment. Our model can predict the tumor growth and morphology due to both promoting and 
inhibitory effects of MMP with variations of tissue environment and will, therefore, be helpful to 
design combination therapies including selective MMP inhibition.  
 
2. The Mathematical Model 
   
There are two major approaches for tumor growth modeling: the first employs continuum models to 
describe the evolution of the tumor in terms of systems of partial differential equations; the second approach 
uses discrete models. A one-millimeter-radius spheroidal tumor contains around one million cells. In large 
scale systems continuum models are more suitable than discrete-cell models.  In a continuum model, the 
cell velocity is obtained from the inertia-less momentum-conservation equation based on Darcy’s law, 
representing the instantaneous equilibrium among forces associated with pressure, cell adhesion, elastic 
forces, forces exchanged with the ECM leading to haptotaxis and chemotaxis due to gradients of 
nutrient/growth factors, and other mechanical effects [46].  The adhesion among cancer-cells is modeled 
by a surface tension at the tumor surface [17, 20, 21, 28, 46-55].  Our study employs a continuum model 
based on previous continuum model of solid tumor growth [19] but is extended here to take into account 
cell motion due to chemotaxis. Following [1], our model assumes that a sharp interface separates the tumor 
from the host tissue and the total density of tumor cells is constant in the tumor interior and drops sharply 
to zero in the tumor exterior,  We neglect necrosis while accounting for apoptosis (programmed cell death). 
Although we do not include the tumor blood flow and necrosis, our model can be extended to incorporate 
these effects.  
We model a single vital nutrient (oxygen) which is required for cell survival and mitosis. Let D be a 
rectangular domain (Figure 1) containing the tumor mass ΩT and the non-cancerous tissue ΩH (including 
the ECM, healthy cells and any other material immediately surrounding the tumor). The following two 
cases will be considered: (i) the absence of blood vasculature in D and (ii) a preexisting vasculature in D. 
The surrounding noncancerous tissue in ΩH contains a variety of host cells such as fibroblasts, macrophages 
and blood vessels, all of which have been shown to be important factors in tumorigenesis [56]. However, 
we have chosen to disregard these aspects of tumor growth to give emphasis on chemotaxis and haptotaxis. 
We assume that cell birth and death are in balance in ΩH and so there is no change in the volume in that 
region.  Let ΣT denote the boundary of the tumor mass ΩT. We choose to focus on the key variables involved 
in tumor cell growth and invasion; nutrient concentration (ρN), MDE concentration (ρM) ECM density(ρE), 
soluble ECM density(ρS ), cellular velocity field (u) and solid pressure (p) We derive a system of coupled 
partial differential equations to model tumor growth in the surrounding tissue and present numerical 
solutions in two spatial dimensions describing the macroscopic dynamics of invasion in different tumor 
microenvironments due to haptotaxis and chemotaxis.  
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2.1 Nutrient Transport  
   
In our model, the net effect of nutrients and growth-promoting and inhibiting factors are described with 
a single nutrient (oxygen). The nutrient concentration satisfies the advection-diffusion-reaction equation:  
 
∇⋅ D
N
∇ρ
N( ) = δNρN( ) IΩ
T
  (1) 
 
Here, DN is the nutrient diffusivity, δN is the rate of nutrient uptake by the tumor cells (assumed constant) 
and IΩ
T
is a characteristic function equal to 1 (0) inside (outside) of the tumor region ΩT . As nutrient 
diffusion is a much faster process than the cell growth, the nutrient concentration equation can be assumed 
quasi-steady. Considering	 the	 velocities	 involved	 in	 tumor	 growth	 [57],	 the	 nutrient	 advection	 is also 
negligible compared to diffusion [58]. We assume that tumor cells uptake nutrient at a greater rate than that 
of noncancerous cells, and so nutrient uptake is negligible in ΩH [59-61]. Furthermore, we assume that there 
is little cellular debris in ΩH and therefore no nutrient decay in that region. The nutrient concentration and 
flux are assumed to be continuous across the tumor boundary.  The two cases that we consider are (i) a low-
nutrient environment (e.g., no pre-existing blood vasculature in the computational domain) and (ii) a high-
nutrient environment (e.g., the presence of a pre-existing network of nutrient-supplying blood vessels in 
the domain). For case (ii), nutrient delivery by the blood vasculature and uptake by noncancerous cells are 
assumed to be in balance outside of ΩH so that the blood vasculature sufficiently delivers nutrient so that 
ρN is a constant (ρN∞) at the boundary of the computational domain. So for case (i), we solve Eq. 1 in the 
entire domain while for case (ii) we solve it only for the tumor region. 
   
2.2 The MDE, Intact ECM and Soluble ECM Density  
   
MDEs are important at many stages of tumor growth, invasion and metastasis, and the manner in which 
they interact with inhibitors, growth factors and tumor cells is very complex. The ECM is a complex mixture 
of macro-molecules; but for simplicity, we represent it with a single concentration. Similarly, we 
characterize MDE and soluble ECM with single concentrations. The production of MDEs and subsequent 
degradation of the ECM play a role in providing room for the tumor to expand into the surrounding tissue. 
MDEs are produced (or activated) by the tumor cells at a constant rate λM and diffuse throughout the tissue. 
Removal of MDEs takes place due to natural decay and by deactivation of the enzymes at a constant rate 
λDM. The equation governing the evolution of MDE concentration is  therefore given by, 
 
 
∂ρ
M
∂t
= ∇⋅(D
M
∇ρ
M
)+ λ
M
(ρ
M0
− ρ
M
)( ) IΩ
T
− λ
DM
ρ
M
 .                              (2) 
 
Here, ρM0 is the maximum sustainable concentration of MDE. Experimental work has found that the MDE 
concentration is kept in check by the opposing anti-proteases secreted by nearby healthy tissue [62]. 
Therefore following the model in [19], we model this effect with a production term that saturates at the 
maximum sustainable concentration. Because the coefficient of diffusion of MDE (DM) is much smaller 
than that of oxygen, the full time-dependent diffusion equation is used. Following [63], MDE advection 
term is not included because diffusion time scale (per second) is very shorter than cell growth time scale 
(per days).  The interactions between cancer cells and the surrounding ECM are known to play an important 
role in carcinogenesis. The intact ECM density is governed by the following equation. 
 
∂ρ
E
∂t
= −λ
DE
ρ
M
ρ
E
/ ρ
M 0
                                             (3) 
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The ECM is considered as non-motile structural matter, so doesn’t have advection and changes in its 
distribution are due to its local degradation by MDEs upon contact, at the rate λDE. Although the ECM 
functions directly as a growth restraint for tumor cells, we have not included it in our model in order to 
investigate the effect of directional migration (via chemotaxis and haptotaxis) on tumor growth and 
morphology. The ECM may also deform and remodel in response to pressure, proteolysis and to insoluble 
ECM macro-molecules released by the cells, but we have not considered this.  The structure of the ECM 
has a profound effect on tumor morphology as demonstrated by the model in [64], however in this paper 
we will consider the ECM as a homogeneous material.  
The soluble ECM is produced from the degradation of ECM by MDE at a rate λDE and diffuses at the 
rate DS. The soluble ECM density is given by [1],  
 
0.( ) /
S
S S DE M E M
D
t
r
r l r r r
¶
=Ñ Ñ +
¶
 (4) 
 
 Following [1], soluble ECM advection term is neglected because diffusion time scale (per second) is very 
shorter than cell growth time scale(per days).  We neglect the repeated breakdown of ECM fragments 
known unlike [1].  In the boundary of the computational domain, we take the boundary conditions ρM = 0, 
ρS = 0 and ρE =ρE∞ (ECM density at far field).  
 
2.3 Cellular Velocity Field  
   
Following previous studies, it is assumed that the tumor
 
is a viscous, inertialess fluid and that all tumor 
cells move with a single cellular velocity field 
!
u .  The tumor boundary moves with the cell velocity at the 
tumor-host interface.  Mathematically, chemotaxis and haptotaxis take the same form as movement of cells 
is directed towards high concentrations of the substrates. The motion of the cancer cells is governed by the 
proliferation pressure p and chemotactic and haptotactic response to soluble ECM and intact ECM 
gradients, respectively.  
 
 
!
u = µ(−∇p + χ
S
∇ρ
S
+ χ
E
∇ρ
E
)                                                                                                   (5) 
  
Here, µ is the mobility coefficient and χS and χE are the chemotaxis and haptotaxis coefficients. We assume 
that the mobility coefficient (µ) accounts for the environmental effects and measures the overall ability of 
tumor tissue to respond to the pressure gradients and also characterizes the permeability of the tumor 
cells. The cell chemotaxis and haptotaxis coefficients are both assumed to be non-negative and constant in 
ΩT. Cancer cell motility depends not only on ECM gradients (haptotaxis) but also on ECM density 
(haptokinesis) as demonstrated by the model in [65]. However, since our focus here is on gradient-driven 
migration, we effectively choose to ignore the dependence of the cancer cell motion on the ECM density in 
the absence of ECM gradients. We assume that the normal velocity is continuous across the tumor boundary. 
The density 
 
ρ
T
 of the tumor tissue in ΩT obeys the following advection-reaction equation. 
 
 
∂ρ
T
∂t
+∇⋅(
!
uρ
T
) = λ
p
ρ
T
ρ
N
/ ρ
N∞
− λ
A
ρ
T                                                                                                   (6) 
 
In the sharp-interface context, there is a sharp interface between the tumor and host regions [17, 19-21, 28, 
48-55].  As mentioned earlier that the total density of tumor cells is constant inside the tumor and drops 
sharply to zero in the tumor exterior.  As cells have a proclivity to remain bound to each other, the constant 
tumor density 
 
ρ
T
is also known as close-packing density. We therefore prescribe 
 
ρ
T
= 0 in ΩH and 
 
ρ
T
= 
1 in ΩT, to obtain 
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∇⋅u = (λpρN / ρN∞ − λA )IΩT                                                                                                                   (7)  
 
We assume that in the tumor region, cell-mitosis is proportional to the amount of nutrient present and that 
volume loss due to cellular apoptosis occurs at the rate λA. We also assume that there is no proliferation in 
the host microenvironment. Lastly, the diffusion of tumor cells is an order of magnitude smaller than 
advection [48] and is therefore neglected. 
 
2.4 Mechanical Pressure  
   
The tumor cells at the continuum level are modeled as a fluid flowing through a porous medium (e.g. 
the ECM). Primarily, tumor growth depends on the balance between expansive forces caused by cell 
proliferation and cell-cell adhesion forces, which maintain the tumor’s compactness. When there is no taxis, 
continuity of the normal velocity across the tumor boundary dictates that there is no jump in the normal 
derivative of p across ΣT; i.e., [µδp/δn] = 0. Assuming  uniform cell-cell and cell-matrix adhesion 
throughout the tumor, the adhesive pressure can be incorporated as a Laplace-Young surface-tension-like 
jump boundary condition at the tumor-host interface ΣT: [p] = pouter – pinner  = Γ*k, where k is the mean 
curvature of the interface and Γ is a constant adhesion parameter analogous to a surface-tension coefficient. 
Thus, the adhesive forces are modeled by a curvature boundary condition on the interface ΣT. This 
representation of adhesion is relatively simple and indirect, however, involving no explicit modelling of 
cell–cell or cell–ECM contact. In these approaches cell-to-cell and cell-to ECM adhesion are modelled as 
tumor shape stabilizing mechanical forces which is supported by the experimentally observed presence of 
surface tension at growing tissue boundaries[66, 67].  The non-cancerous tissue in ΩH is assumed to be 
close enough to the tumor to be affected by the pressure changes within the computational domain. The 
pressure is assumed to satisfy the boundary condition at the computational domain, p = 0; i.e., there is no 
extra pressure outside the computational domain. The MDE activity is centered almost exclusively within 
a narrow region adjacent to the tumor surface, as it is kept in check by the opposing anti-proteases secreted 
by nearby healthy tissue [62]. Similarly we assume that the chemotaxis of gradients of soluble ECM acts 
only near the interface. Therefore, we take taxis coefficients as piece-wise constant terms i.e., in the tumor 
region they are positive numbers and outside the tumor, they are set to zero. Thus, the pressure satisfies the 
following normal jump condition. 
                    
[ ] [ ] [ ]S S E Ep n n nc r c r¶ ¶ = ¶ ¶ + ¶ ¶     (8)   
 
We define the net pressure responsible for the tumor growth, ( )
net E E S S
p p c r c r= - +  
So Eq. (5) becomes, 
 
!
u = −µ∇p
net
. (9) 
 
By combining Eqs. (7) and (9), we obtain the following governing equation for pnet . 
 
µ∇2pnet = −λp(ρN / ρN∞ )+ λA( ) IΩT    (10) 
 
with the following jump conditions on pressure and its normal gradient across the tumor boundary. 
 
[ ] [ ]0, ( ) Tnet net S S E Ep n pµ µ k c r c r S¶ ¶ = = G+ +                                                                          (11)   
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Once the net pressure is known, we can calculate the cell velocity 
!
u  from Eq. 9. In the rest of the paper 
we refer net pressure as pressure. 
 
2.5 Nondimensionalization  
   
Before solving the system of governing equations numerically, the parameters and variables are 
nondimensionalized using the following characteristic scales [19]. 
 
 L ≡ D
N
δ
N
= 200µm ,  τ ≡ λp,max
−1
=1/max proliferationrate =1.5days                               (12) 
 
The length scale L corresponds to the maximum invasion distance at the early stage of tumor invasion. The 
characteristic tumor pressure p
T = L
2
λp,max µ  is that which results in maximum cell proliferation with a 
nondimensional cell speed of unity. As reference densities, we use the far-field nutrient concentration
 
ρ
N∞
, the intact-ECM density 
 
ρ
E∞  and the maximum sustainable MDE and soluble-ECM densities  ρM 0  and ρS 0
, respectively. The field variables are made dimensionless as specified in Table 1, while non-dimensional 
parameters are defined in Table 2. The dimensionless governing equations in terms of the nondimensional 
variables and parameters defined in Tables 1 and 2 are provided below. We use the same symbols for the 
non-dimensional variables as those used for the respective dimensional variables defined above.  
 
The dimensionless governing equations can then be written in the following general form: 
  
 
∂ρ
M
∂t
= ∇⋅(D
M
∇ρ
M
)+ λ
M
(1− ρ
M
)( ) IΩ
T
− λ
DM
ρ
M
∂ρ
S
∂t
= ∇⋅(D
S
∇ρ
S
)+ λ
DE
ρ
M
ρ
E
∇2ρ
N
= ρ
N
IΩ
T
,
∂ρ
E
∂t
= −λ
DE
ρ
M
ρ
E
∇2 p
net
= (λ
A
− λ
P
ρ
N
)IΩ
T
,
!
u = −∇p
net
⎫
⎬
⎪
⎪
⎪
⎪
⎭
⎪
⎪
⎪
⎪
 (13) 
 
The following nondimensional initial and boundary conditions are applied. 
( )
( )
[ ] [ ] ( )
0
1, 0
1, 0
0,
T
E M S t
N E M S net
net net S S E E
p
p n p
r r r
r r r r
k c r c r
¥
=
S
S
ü= = =
ïï
= = = = = ý
ï
¶ ¶ = = G + + ïþ
  (14) 
 
The tumor boundary moves with the cell velocities at the tumor-host interface. The haptotactic 
coefficient =2600 cm
2
/s/M was estimated to be in line with that calculated in [68] and the parameter ρ
E∞
=10
-8
 - 10
-12
 M is found from [69].  We take ρ
E∞ =8.42*10
-7
 M.  Estimates for the ECM degradation and 
MDE diffusion, production and degradation coefficients are not available since these are very difficult to 
obtain experimentally [70]. We have used [19] for these values. According to [1], the MDE and soluble 
ECM diffuse at the same rate, so we have used to be same as in [19]. Table 2 also has all the references 
from where we have chosen our parameter values 
  
3. Numerical Method  
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The set of governing equations, Eqs. (13) and (14), are solved throughout the entire computational 
domain, on a uniform 2D Cartesian mesh, except for the Poisson equation for ρ
N
, which for high- nutrient 
case is solved for the tumor region ΩT  only. Because we anticipate frequent and complex morphological 
tumor-surface changes we use the level-set method, based on a reformulation of a model proposed in [22]. 
Let φ be an auxiliary level-set function whose zero level set denotes the boundary ΩT of a tumor growing 
into a surrounding, non-cancerous tissue, satisfying φ < 0 inside ΩT, φ> 0 outside ΩT , and φ = 0 on the 
tumor boundary ΣT . We update the position of the interface by solving the PDE, 
     
 
 
∂φ
∂t
+
!
u ⋅∇φ = 0  (15)  
  
We solve Eq. (15) with the semi-Lagrangian scheme developed by Aldredge [71] using upwind transient 
interpolation modeling [72, 73]. The scheme provides third-order spatial accuracy and shape preservation.  
We use the immersed interface method [74] to solve for pressure, which is discontinuous across the tumor-
host interface, in accordance with the boundary conditions specified above—i.e., Eq.(11). This requires 
calculation of normal vectors and curvature at the interface using the level-set function. For accurate normal 
and curvature calculation we reinitilize φ at every time step by solving the following equation [75, 76]. 
 
∂φ
∂τ
− sign(φ 0 )(1− |∇φ |) = 0   (16) 
 
where φ
0
 is the level set function prior to reinitialization and τ is the reinitialization time, reset to 0 at the 
beginning of each reinitialization process. We discretize the temporal derivative using a third-order total-
variation-diminishing Runge-Kutta method (TVD-RK) and approximate sign(φ
0
) |grad(φ)| with the fifth-
order WENO scheme [77]. However when two interfaces are in close contact, level set functions develop 
singularities that yield inaccurate normal vectors and curvatures when applying traditional discretization 
methods. In these cases, we construct the level-set function on a local subgrid where we can accurately 
calculate the normal vectors and curvature using standard discretization methods [18, 78]. As the velocity 
field near the interface is very sensitive to variations in the curvature, we use a gaussian smoothing filter to 
damp high frequency pertubations in the speed and interface position, in accordance with [18].   
 
The steps for solving the system of PDEs governing the tumor growth in our model are as follows. 
  
(i) Initialize a level set function φ to represent the interface ΣT.  
(ii) Solve the system of governing equations given in Eq. (13) subject to the initial and boundary 
conditions in Eq. (14) to obtain ρM , ρN , ρS , ρE , pnet  and 
!
u . The Alternating Direction Implicit (ADI) 
method [79] is used to obtain ρM   and ρS , while ρE  and pnet  are obtained using the second-order 
Runge-Kutta and immersed-interface methods, respectively.  
(iii) The velocity field  
!
u  is obtained by using central differences to estimate the pressure gradient. 
Filter the velocity field using a gaussian smooting filter to remove high frequency noise. 
(iv) Set the next overall time step, in accordance with the Courant-Friedrichs-Lewy (CFL) requirement 
for numerical stability. 
(v) Update the position of the boundary ∑T by solving Eq. (15) for the level-set function φ with the 
newly obtained velocity field  
!
u  . 
(vi) Reinitialize φ to maintain it as a signed distance function, by solving Eq. (16) 
(vii) Repeat steps (ii)-(vi) for each new time step. 
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4. Results and Discussion 
 
We investigate the effect of haptotaxis and chemotaxis on tumor growth in a computational domain Ω 
of size [0, 20] × [0, 20] with grid size 256X256. An initial tumor shape which is slightly elliptical and 
centered on the domain is prescribed by the following equation. 
 
(x −10)
2
2.1
2
+
(y −10)
2
1.9
2
= 1   (17)  
 
This elliptical tumor’s major and minor axes lengths are 840 and 760 µm, respectively (for the length scale 
L=200 µm). A one-millimeter-radius spheroidal tumor contains around one million cells [41]. The tumor 
initial shape is elliptical for initiating a small perturbation (to break symmetry) on the tumor size 
which has been also used as an initial condition by other model.  To minimize the influences of the 
computational-domain boundary, we stop the simulation when the tumor boundary is within 4 distance units 
of the boundary of the computational domain. We assume that the ECM is initially not degraded (i.e., 
ECM=1, soluble ECM=0 and MDE=0 in the entire domain) and investigate tumor growth in nutrient-rich 
and nutrient-poor microenvironments with chemotaxis and haptotaxis. Initial nutrient distribution is not 
required as Eq. 1 is quasi-steady. To assess tumor growth, we calculate the tumor area and surface perimeter 
at regular intervals.  Following [17], we define the following parameters to characterize the morphological 
characteristics of the tumor. 
  
Shape parameter: S = (Perimeter) 
2
/ (4π*Area) 
Length Scale: LS=2*Area/Perimeter 
 
The shape parameter S is a measure of the non-circularity of the tumor shape; when S=1, the tumor shape 
is a circle. The length scale LS is a measure of the smallest dimension of the tumor. For example, for a 
rectangular tumor with width W and length L, LS = LW/ (L + W) and LS = W if W<<L. For better 
understanding of these parameters refer to Fig. 2, which shows how S and LS vary with tumor morphology. 
 
4.1 Effect of chemotaxis in a nutrient-poor microenvironment 
 
Earlier studies using hybrid (discrete–continuum) model including haptotaxis [31, 32, 64]  
demonstrated that a fingered tumor morphologies can be induced by lowering the nutrient concentration (in 
the microenvironment) even in a homogeneous ECM whereas the tumor is non-invasive for nutrient rich 
environment. Here, we investigate the influence of soluble ECM as a chemoattractant, in addition to the 
haptotactic effects, on tumor growth and morphology in a nutrient-poor environment, which has not yet 
been reported in the literature. According to the work of Perumpannani et al. [1], invasiveness decreases as 
the chemotactic coefficient is increased. As hypoxia leads to instabilities in tumor growth, the inhibitory 
effects of soluble ECM gradients during tumor invasion should be investigated along with hypoxia and 
haptotaxis subject to variations in the magnitude of the chemotaxis coefficient.  
We consider a tumor with an initial shape defined by Eq. 17 growing in a low-nutrient environment. 
Relevant baseline parameter values are listed in Table 2. Table 3 shows the values used for parameter 
sensitivity studies. In order to understand the effect of chemotaxis on tumor growth and morphology, we 
first compare the cases of no taxis (no directed cell motion) and haptotaxis only and chemotaxis only.  The 
morphological evolution of the tumor in the computational domain with time are shown in Fig. 2 for the 
cases of no taxis (Fig. 2a-b), haptotaxis only (with coefficient χE=1) (Fig. 2c-e) and chemotaxis only (with 
coefficient χS=10) (Fig. 2f-g). The ECM gradients near the boundary of the tumor are responsible for the 
motion of the tumor cells via haptotaxis. The tumor develops four large, symmetric bulbs with very narrow 
necks (Fig. 2e), which continue to spread in the computational domain and eventually split into four pieces. 
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If we consider chemotaxis only (with χS=10), the tumor stops growing after a certain time and the 
morphology is stable, i.e. circular (Fig. 2g).  So the instability due to the perturbed initial tumor shape does 
not grow in spite of hypoxia, due to the inhibitory effect of chemotaxis.   
The combined effects of chemotaxis and haptotaxis on tumor morphology are shown in Fig. 3 for χE=1 
and χS=10.  The contours of MDE, ECM and soluble ECM at different times are shown in Fig. 4.  Both 
MDE and soluble ECM are diffusible, so we notice smooth contours unlike for ECM contours. Soluble 
ECM is made from ECM upon degradation, so where ECM is the lowest, soluble ECM is the greatest. 
During earlier times the tumor elongates along the y-axis and bulges are formed along left and right sides, 
which continue to grow deeper with increasing time. We notice that while the initial tumor shape 
perturbation is along x-axis, the tumor-surface instability grows along the y-axis due to the combined effects 
of chemotaxis and haptotaxis. This is due to the fact that during early times the ECM gradients are greatest 
on the left and right sides of the tumor, which causes the soluble ECM gradients to be greatest in these 
regions. The chemotactic influence prevents tumor growth due to cell proliferation and haptotaxis in these 
regions, while the top and bottom surfaces grow. The net effect is tumor elongation along y-axis. The 
growth of the left and right bulges can be explained by the plots of gradients of ECM and soluble ECM in 
Fig. 5.  As soluble ECM is diffusible, its gradients are smaller (as seen in Fig. 5a) than the gradients of 
ECM (Fig. 5b) in the computational domain. The net gradients of ECM and soluble ECM (similar to Fig. 
5b qualitatively) causes the growth of the left and right bulges and the formation of the two symmetric buds. 
The gradients in regions near the top and bottom tumor surfaces are smaller and uniform (not shown here) 
which promote slow and uniform growth on these regions.  
So for combined effects of haptotaxis and chemotaxis, the tumor morphology is still unstable and 
different from that with only haptotaxis considered (Fig. 2c-e). We can conclude, therefore, that for these 
extents of chemotaxis and haptotaxis, the instability due to cell-proliferation and haptotactic attraction of 
ECM gradients is not counteracted by the chemotactic attraction of soluble ECM gradients. The influence 
of the extent of chemotaxis on tumor shape and growth and morphology is shown in Fig. 6 and Fig.7 
respectively using different values of chemotaxis coefficients listed in Table 3. If we increase the 
chemotaxis coefficient fivefold (i.e., χS=50 and χE=1), the tumor growth further slows and the bulbs are 
formed later (compared to the growth with χS=10 and χE=1), after the tumor has elongated vertically to a 
greater extent. However, for both values of the chemotaxis coefficient considered, tumor growth is unstable 
and a thin neck forms which may split into two symmetric buds. The tumor growth is stable when we 
increase the chemotaxis coefficient tenfold (i.e., χS=100 and χE=1). As is evident in the plots of tumor area 
and perimeter versus time (Fig.7a and 7b, respectively), chemotaxis slows tumor growth and for χS=10, 
χE=0 and for χE=1, χS=100 tumor growth stops after a certain time when cell motion due to proliferation 
and haptotaxis are balanced by the chemotactic motion.  
We can gain a more detailed understanding of the invasion process resulting from the combined effects 
of chemotaxis and haptotaxis by examining the evolution of the shape parameter S and length scale LS, 
plotted in Figs. 7c and 7d, respectively. Initially, S is constant and nearly unity as a result of uniform tumor 
growth, while LS increases with increasing tumor size. Later, S steadily rises as the tumor elongates, 
becomes increasingly noncircular and forms bulges for both χE=1 (with χS=0) and with combined effects of 
haptotaxis and chemotaxis (with χE=1 and χS=10 and 50). The LS concomitantly decreases, since the width 
of the tumor decreases as the tumor elongates. For both χS=10 (with χE=0) and χS=100 (with χE=1), shape 
parameters (Fig. 7c) are always near unity which indicates stable growth even there is initial shape 
instability, while length scales (Fig. 7d) eventually become relatively constant with increasing time.   
Thus, considering only chemotaxis can result in stable tumor growth in nutrient-poor 
microenvironments. When the effects of haptotaxis are considered, we find that chemotaxis inhibits tumor 
growth and changes the overall growth response of the tumor. However, the stability of tumor morphology 
strongly depends on the extent of chemotaxis.  
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4.2 Effect of chemotaxis in a nutrient-rich microenvironment 
 
Previous studies report that the tumor growth is compact (non-invasive) in nutrient-rich environments 
and even haptotaxis has no distinct effect on morphology [32]. Here, we investigate the effects of 
chemotaxis for tumors growing in high-nutrient environments, not previously addressed in the literature. 
This case applies to a tumor with an adequate supply of nutrient from either pre-existing or newly developed 
vasculature through angiogenesis. As angiogenesis inhibitors are used with the intent of halting or slowing 
tumor growth, the inhibitory effects of soluble ECM gradients during tumor invasion should be investigated 
subject to variations in the value of the chemotaxis coefficient, considering haptotaxis and an adequate 
supply of nutrients in the tumor microenvironment.  
First, we consider the case when there is only haptotaxis-induced cell movement (with χE=1) and tumor 
growth depends on cell proliferation and haptotaxis. Relevant values for baseline parameters and parameter 
sensitivity studies are given in Tables 2 and 3, respectively.  The evolution of the tumor morphology with 
time is displayed in Fig. 8a-d for this case in which the nutrient concentration is always maximum (ρN=1) 
on the tumor boundary (as shown in Fig. 8e). The increased nutrient supply in this case increases 
proliferation and, in turn, causes large solid pressures (cf. Fig. 8f) to form in the proliferating region, which 
cause the tumor to grow even more rapidly, further enhancing this effect.  The tumor develops an H-shaped 
structure in this case. The morphologies here are very similar to those for the case without taxis, as described 
in [48], although the tumor grows faster due to the combined effect of cell proliferation and haptotaxis. If 
we consider chemotaxis only (with χS=10), the tumor morphology is not stable (similar to that shown in 
Fig. 8), unlike for the case of growth in a nutrient-poor microenvironment. The dual influence of chemotaxis 
and haptotaxis on tumor morphology for χE=1 and χS=10 is also similar to that suggested in Fig. 8.   
Fig. 9 shows the evolution of tumor morphology with a fivefold increase in the chemotaxis coefficient 
(i.e., χE=1 and χS=50). We observe that while the initial perturbation is along x-axis, the tumor surface   
instability grows along the y-axis due to the combined effect of chemotaxis and haptotaxis. During early 
times, these morphologies are similar to those shown in Fig. 3 for tumor growth in a nutrient-poor 
microenvironment due to the combined effects of chemotaxis and haptotaxis with χE=1 and χS=10. Left and 
right bulges are formed while the surfaces near the top and bottom of the tumor continue to bend inward 
without reconnecting, growing bigger and spreading throughout the computational domain. Similar 
morphologies are observed with a tenfold increase in the chemotaxis coefficient (i.e. χE=1 and χS=100), 
although with slower rates of growth. If the chemotaxis coefficient is further increased, by a factor of fifty 
(i.e., χE=1 and χS=500), stable growth is achieved.  For different values of chemotaxis coefficients (listed 
in Table 3) the tumor morphologies and the growth dynamics are shown in Fig. 10 and Fig. 11, respectively.  
We notice that during early times the tumor area, perimeter and shape parameter all are nearly similar 
in Fig.11a-c. This is due to the fact that the large solid pressure caused by the faster proliferation in the 
nutrient-rich microenvironment is substantially greater than the change in solid pressure due to chemotaxis 
and haptotaxis. Later on, the influence of chemotaxis alone and the combined influence of chemotaxis and 
haptotaxis become evident in the results plotted as the tumor area, perimeter and shape parameter increase 
with time. With increasing extent of chemotaxis, tumor growth slows, but does not become stable. Thus, 
our simulations of tumor growth in nutrient-poor and nutrient-rich environments clearly show that 
chemotaxis can inhibit tumor growth irrespective of the level of nutrient concentration in the 
microenvironment, and the stability depends on the extent of chemotaxis. However, the effect of chemotaxis 
is more pronounced for tumor growth in nutrient-poor microenvironments.  
 
4.3 Effect of biophysical parameters in nutrient-poor and nutrient-rich 
microenvironments 
 
Parameter sensitivity studies for haptotaxis show that variations of the MDE diffusion coefficient DM, 
ECM degradation rate λDE, MDE production rate λM and MDE decay rate λDM change tumor growth greatly 
[70, 80]. The chemotaxis-haptotaxis model in  [1] investigated the effects of varying ECM degradation rate 
13 
 
	
λDE and MDE production rate λM in one spatial dimension and predicted that the tumor invasiveness will 
first increase with increase in λDE and/or λM,  but then decrease for excessive increase in λDE and/or λM. We 
will investigate the influence of various biophysical parameters related to soluble ECM production on tumor 
growth and morphology using our chemotaxis-haptotaxis model, accounting for variations in nutrient 
concentration, which has not been previously reported in the literature. In particular, we consider the effect 
of varying the ECM degradation rate, λDE and the MDE production rate λM, on the morphology of tumors 
growing in nutrient-poor and nutrient-rich microenvironments using the baseline values in Table 2. 
We consider increases in the value of λDE by factors of 10 and 100 (i.e. λDE =0 .10 and λDE=1.0, 
respectively), representing increased ECM degradation and concomitant increased production of soluble 
ECM. The tumor growth under the combined influences of haptotaxis and chemotaxis (i.e., χE=1 and χS=10) 
is unstable (as shown in Fig. 3). The resulting tumor shapes due to the effects of increasing λDE are displayed 
in Fig. 12 for both low and high nutrient environments. It is clear that as λDE increases, the tumor elongates 
more vertically for the low-nutrient case. For the nutrient-rich case, tumor morphologies also change (more 
vertical elongation which means more invasion into the host tissue) with increasing λDE. If we increase λDE 
further, i.e., λDE =10, the tumor growth slows down. Although the shapes that evolve in these two 
environments are qualitatively different, there are shape instabilities in each case that are not fully damped 
due to increased soluble ECM production resulting from increased ECM degradation. 
Fig. 13 demonstrates the effect of increasing λDE on tumor growth dynamics and morphology with time. 
For both environments, the instability develops earlier with increasing λDE, although the slopes of the curves 
increase greatly with increasing λDE for low-nutrient environments. This is because the gradients of ECM 
and soluble ECM both increase as λDE increases. As soluble ECM gradients will inhibit growth, and ECM 
gradients will accelerate growth, faster growth indicates that the effects of haptotaxis become stronger with 
increasing λDE for tumor growth in both environments. Most importantly, for very large rate of λDE (=10) 
we see that the growth rate again slows down for both environments. To support this fact, we tabulate the 
time at which tumor shape parameter is 1.5 with increasing λDE by an order of magnitude in Table 4. So, 
our model predicts an increase in invasiveness with increase in λDE and decrease in invasiveness at very 
high levels of ECM degradation for both microenvironments. More importantly, although showing biphasic 
growth responses with increase in λDE, the tumor growth is still unstable for this extent of chemotaxis. 
Next, we consider the effect of increasing MDE production. If MDE is produced at a greater rate, ECM 
will be degraded more rapidly while fragments of ECM production will increase. Thus, greater MDE 
production also favors both haptotaxis and chemotaxis.  Fig. 14 shows the resulting tumor shapes as λM is 
increased from 10 to 1000 (in increments of 10). Tumor shapes change greatly with increasing λM for the 
low-nutrient case, while remaining unchanged for the nutrient-rich case.  The effects on tumor growth and 
morphology with time are shown in Fig. 15, where it is clear that the tumor develops instability faster for 
both environments with increasing λM. Table 5 shows the time at which tumor shape parameter is 1.5 for 
increasing λM, which also supports this fact.  However, the slopes of the curves remain essentially 
unchanged with increasing λM for nutrient-rich tumor growth and decrease (except for area vs. time in Fig 
15a) with increasing λM for the case of nutrient-poor tumor growth. This indicates that increasing λM has a 
greater influence in the nutrient-poor case, in terms of both tumor growth and morphology. Faster growth 
with increasing λM means that the effect of haptotaxis is greater than that of chemotaxis. 
Our chemotaxis-haptotaxis model therefore predicts that increasing λDE and λM, change the overall 
growth response of the tumor irrespective of the nutrient concentration in the tumor microenvironment.  
Furthermore for all values of λDE and λM, the tumor morphologies are unstable with χE=1 and χS=10. 
Although increase in λDE shows the biphasic tumor growth response for both environments as predicted in 
[1], the stability depends on the strength of chemotaxis. Decreasing the MDE production rate increases the 
chemotactic influence irrespective of the concentration of nutrient in the tumor microenvironment.  
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4.4 Chemotaxis and surface-tension in a nutrient-poor microenvironment 
 
Tumor cells tend to adhere less to their neighbors [81] and must lose their adhesion to other cells to 
enable malignant invasion [82]. Cell-cell adhesion mediated with E-cadherin (a calcium-regulated adhesion 
molecule expressed in most normal epithelial tissues) prevents invasiveness of cancer cells [83]. For 
nutrient-poor tumor growth, increasing adhesion can limit the rate of tumor fragmentation and the extent 
of tissue invasion [17]. Morphological instabilities were observed for  nutrient-poor tumor growth, with the 
degree of instability increasing greatly with decreasing surface tension [23]. The fingering tumor cell 
population generally have low cell adhesion and oxygen consumption rates [32]  and are observed for a 
combination of the strength of cell-cell adhesion and haptotaxis [33]. We demonstrate in section 4.1 that 
chemotaxis due to the gradients of soluble ECM can prevent tumor shape instabilities developed due to 
hypoxia and haptotaxis. In this section, we investigate the effect of surface tension and chemotaxis, in 
addition to haptotactic effects on tumor growth and morphology in nutrient-poor environments using the 
values listed in Tables 2 and 6. 
If we consider chemotaxis only (with χS=10), the tumor stops growing after a certain time and the 
morphology is stable for both medium and low surface tension ((Γ =0.05 and Γ =0.01, respectively).  Thus, 
in the absence of haptotaxis, instability of the initially perturbed tumor shape is suppressed, despite the 
hypoxic and low-adhesion microenvironment conditions due to the inhibitory effect of chemotaxis. Next, 
we investigate the dual effects of haptotaxis and chemotaxis subject to variations of the chemotaxis 
coefficient.   The tumor morphological evolution for the low surface-tension coefficient accounting for the 
combined influence of chemotaxis and haptotaxis (χE=1 and χS=10) is shown in Fig. 16.  The tumor 
develops four large, symmetric bulbs with very narrow necks (Fig. 16c), which continue to spread in the 
domain and eventually split into four pieces. Qualitatively, these morphologies are very similar with 
haptotaxis (χE=1) but no chemotaxis and with medium surface-tension (cf. Fig. 2c-e)   
The combined effects of chemotaxis and haptotaxis (for χS=50 and χE=1) on tumor morphology at 
different times are as shown in Fig. 17. Increased growth inhibition due to chemotaxis forces the tumor to 
grow more slowly. During earlier times the tumor elongates along the y-axis and bulges are formed along 
left and right sides, which continue to grow larger with increasing time. The influence of the extent of 
chemotaxis on tumor growth and morphology is shown in Fig. 18 for different values of surface tension.  
The tumor morphologies are unstable for both values of the chemotaxis coefficients (χS=10 and χS=50) and 
surface-tension coefficients considered, a thin neck forms; the neck may eventually break, splitting the 
tumor into symmetric buds. Therefore for these extents of chemotaxis and haptotaxis, the instability due to 
cell-proliferation and haptotactic attraction is not fully countered by the chemotactic attraction of soluble 
ECM gradients, even with a fivefold increase in surface tension. We notice that the tumor morphologies 
are very similar for both surface tension coefficients when χS=50 and χE=1. The morphologies are stable 
when we increase the chemotaxis coefficient tenfold (i.e., χS=100 and χE=1) which is also observed for 
medium surface tension. So the effect of surface tension decreases as we increase the extent of chemotaxis. 
Thus, considering only chemotaxis can result in stable tumor growth in nutrient-poor 
microenvironments irrespective of the level of adhesion. When effects of haptotaxis are considered, we find 
that chemotaxis inhibits tumor growth and changes the overall growth response of the tumor, as a result of 
haptotaxis and the loss of cell-adhesion. Moreover, by increasing the extent of chemotaxis tumor growth 
can be controlled (stabilized) in low-adhesion conditions; and as the coefficient of chemotaxis increases the 
influence of cell-adhesion on tumor growth and morphology decreases and becomes eventually negligible 
(stable growth). 
 
4.5 Effect of chemotaxis in a low-proliferation microenvironment 
 
Tumor cells undergo a variety of biophysical responses in hypoxic conditions, including activation of 
signaling pathways that regulate proliferation, death, angiogenesis and invasion. Therefore hypoxia is 
associated with poor prognosis and resistance to radiation therapy [84]. Rapidly growing tumors invariably 
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contain hypoxic regions. Adaptive response to hypoxia may lead to low cell proliferation. Chemotaxis of 
tumor cells up nutrient gradients produces branched invasive structures in conditions of low cell 
proliferation [30] in hypoxic and low-proliferation environments. Thus, it is important to study the effects 
of chemotactic inhibitory influences on tumor growth and morphology in hypoxic environments for the 
case of low mitosis rate. Here, we examine the influence of chemotaxis on the dynamics and morphology 
of tumors for this case, not previously addressed in the literature.  
First, we consider the case when there is only haptotaxis-induced cell movement and tumor growth 
depends on cell proliferation and haptotaxis. Relevant parameters values are given in Tables 2 and 7. The 
tumor growth is unbounded but circular (i.e., stable) despite haptotaxis (with χE=1) due to low cell 
proliferation. Next, we consider the combined effect of chemotaxis and haptotaxis. The evolution of the 
tumor morphology with time is displayed in Fig. 19 for χE=1 and χS=10. We observe that while the initial 
perturbation is along x axis, the tumor surface instability grows along the y axis due to the combined effect 
of chemotaxis and haptotaxis. During early times, these morphologies are similar to those shown in Fig. 3 
for tumor growth in a nutrient-poor environment due to the combined effects of chemotaxis and haptotaxis, 
with χE=1 and χS=10. A possible cause is provided in sect. 4.1. The major difference from sect. 4.1 is that 
in this case tumor shape is stable for haptotaxis only and there is unstable shrinkage when combined effects 
are considered.  So our model demonstrates that chemotaxis in low mitosis environments can lead to the 
development of instability, although the chemotactic pull works in the opposite direction of that of invasion. 
Fig. 20 shows the growth dynamics of the tumor for different chemotaxis coefficients. We notice that 
the tumor starts growing (unstable as S>1 in Fig. 20c) for χE=1 and χS=10 after initial shrinkage whereas 
with a fivefold and ten-fold increases in the chemotaxis coefficient, the tumor shrinks with time and this 
shrinkage is stable (S~1 as depicted in Fig. 20c). This is also true for the case of chemotaxis only. However 
for this range of chemotaxis coefficients, length scale always decreases with time (cf. Fig. 20d). Both stable 
and unstable shrinkage were predicted in [28] without considering any taxis  rather considering the relative 
rate of mitosis to the relaxation mechanisms (cell mobility and cell-cell adhesion) and the ratio of apoptosis 
to mitosis with low, moderate and high vascularization. Our model predicts a biphasic response of the tumor 
in terms of stability with increase in chemotaxis coefficient when haptotaxis alone does not lead to 
instability.   For both low and high values of chemotaxis coefficients the growth is stable and for medium 
values it is unstable. Therefore, chemotaxis has a stronger influence in low-proliferation environments. 
We now consider an increase in the strength of haptotaxis. If we increase the haptotaxis coefficient 
five-fold (i.e., χE=5) and take a chemotaxis coefficient χS=10, the morphologies shown in Fig. 21 are 
obtained, which are very similar to those obtained for the case of haptotaxis only, with χE=5. If we consider 
chemotaxis only (with χS=10), the tumor morphology is stable. The dual influence of chemotaxis and 
haptotaxis on tumor morphology for χE=5 and χS=50 is also similar to that suggested in Fig. 21.  The tumor 
morphologies and growth dynamics obtained for different values of taxis coefficients are shown in Fig. 22 
and Fig. 23, respectively. We notice from Fig. 23 that during early times the tumor starts shrinking due to 
chemotactic movements, but later becomes unstable (S>1in Fig. 23c) for χS=50.  This is due to the fact that 
the instability caused by haptotaxis is not completely damped out by chemotaxis. For χS=100 (with χE=5) 
and χS=10 (with χE=0) there is stable (as S~1 in Fig. 23c) tumor shrinkage. With an increasing extent of 
chemotaxis, the tumor area, perimeter and length scale all decreases with time.  
In summary, our simulations of tumor growth in nutrient-poor and low-proliferation environments 
clearly show that chemotaxis can inhibit tumor growth, although stability in all cases is not achieved. The 
tumor shows biphasic stability response due to chemotaxis and may act as a growth destabilizing factor 
when the haptotaxis alone does not lead to instability. Both stable and unstable shrinkage are possible 
depending on the strength of chemotaxis. Therefore, anticancer therapies utilizing chemotaxis for low 
proliferation environment should be designed carefully. 
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5. Conclusion 
 
To better target MMPs for cancer treatment, an appreciation of their many, often competing influences 
on cancer progression is needed. Most of the literature supports the notion that the sum of MMP action 
promotes cancer progression, however the actions of the MMPs that negatively regulate cancer progression 
have received relatively little appreciation. We have proposed a two-dimensional continuum model for the 
growth and invasion of tumor cells into healthy tissue that focuses on four key components implicated in 
the invasion process: tumor cells, intact ECM, MDE, soluble ECM and nutrient, which are initially 
homogeneous in the tumor microenvironment. The directed cell motions due to chemotaxis and haptotaxis 
are systematically modeled (along with cell motion due to cell proliferation and adhesion through a 
curvature boundary condition at the tumor interface), and the motility-retarding effects of soluble ECM by 
chemotaxis on the tumor-invasion process have been investigated. The extents of chemotaxis, 
degradation/production of ECM/soluble ECM by MDE and the production rate of MDE are investigated as 
critical factors in the invasion process.   
Tumor growth, morphology and invasion are substantially characterized by whether the tumor is 
growing in a nutrient-rich or nutrient-poor microenvironment. Our simulation results show that the stable 
morphologies can be found in both microenvironments for stronger chemotactic movement, although the 
values of the chemotaxis coefficient required for stabilizing nutrient-rich tumor growth are greater. 
Although increasing the MDE production and ECM degradation rates changes the overall growth response 
of the tumor, these rate do not significantly affect stability. Moreover, increasing MDE production rate 
strengthen haptotactic movement more than that of chemotaxis. There is an optimum ECM degradation rate 
that results in maximum growth in both environments, but stability is not obvious unless the chemotaxis 
coefficient is increased.   
Previous studies have linked low oxygen levels and loss of adhesion in tumor cells as a contributing 
factors in the development cancer. So the motility-retarding effects of soluble ECM by chemotaxis on the 
tumor-invasion process are then investigated for low cell adhesion and low proliferation in a hypoxic 
environment.  When chemotaxis of soluble ECM gradients is included, the effect of adhesion on the tumor 
shape largely depends on the extent of chemotaxis. In the case of low cell-proliferation, chemotaxis has 
greater influence, and the tumor may shrink in shape with increasing chemotaxis, an effect not observed 
for cases of greater cell proliferation. Both stable and unstable shrinkage and biphasic response in terms of 
stability are predicted by our model. More importantly, in some cases chemotaxis can result in early onset 
of instability where the tumor growth induced by haptotaxis alone is stable. Thus, combining anti-protease 
therapy with haptotactic blockade to treat cancer as suggested in [1] should be conducted carefully in low-
cell-proliferation conditions.  
While there are extensive researches on the prohibiting effects of MMP (by creating structural gradients 
of insoluble ECM and associated haptotactic motion) on tumor growth and morphology; our model is the 
first to investigate the inhibitory effects of MMP (by chemotaxis due to soluble ECM gradients) with 
variations in nutrient availability in the tumor microenvironment. We have also investigated the influence 
of chemotaxis due to soluble-ECM gradients, for tumors growing in hypoxic environments with varying 
extents of cell adhesion and cell proliferation rates which was not reported before. These new insights into 
the growth-inhibiting influence of fragments of ECM through chemotaxis will have important implications 
on the understanding of tumor-invasion processes and, most importantly, on the development of promising 
anti-cancer therapeutics. So, the results of our study are useful in advancing our understanding of how the 
microenvironment may affect tumor invasion at the macroscopic scale and thus will be helpful in the design 
of cancer therapy. 
Most forms of invasive cancers are resistant to the traditional chemotherapy focusing on cytotoxic drugs 
for killing cancer cells  and metastasis is responsible for 90% of patient deaths [85] despite recent advances 
in drug delivery methods. Although there has been huge amount of evidence implicating the critical 
roles of MMPs in various stages of cancer growth and progression, we still do not thoroughly understand 
the critical roles of MMPs in the complex cancer microenvironment, as evidenced by the clinical failure 
17 
 
	
of first generation MMPIs in phase III trials [86] despite preclinical data indicating that MMPIs have 
great potential for therapeutic use. As we discussed, the interaction between tumor and its 
microenvironment plays the crucial role during tumor-invasion processes, therefore, further studies 
should be carried out to understand comprehensive MMP roles that correlate with cancer progression or 
drug responses, which is crucial for the clinical development of MMPIs and other cancer therapies.  Our 
study will help cancer researchers to design experimental studies to more closely mimic in 
vivo scenarios for understanding the accurate knowledge of functions of  MMPs. Therefore, the results 
of our study will bring new light to the field of clinical trials so that pharmaceutical companies will begin 
investing in a MMP inhibitor program.  
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Figure 1: Computational domain displaying the tumor enclosed in host tissue 
  
Figure 2: Tumor boundary in nutrient-poor environment for no taxis, haptotaxis only and chemotaxis only 
 
  
 
Figure 3: Tumor boundary for χE =1 and χS =10 in nutrient-poor environment at (a) t=40, (b) t=60, (c) t=80 
and (d) t=100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4: Contours of MDE ((a) and (b)), ECM ((c) and (d)) and soluble ECM ((e) and (f)) at t=40 and 80 
respectively
 
 
 
  
 
Figure 5: Gradients (near left bulge inside blue box in Fig. 3b) in nutrient-poor environment for χE =1 and 
χS =10 at t=60 (a) Soluble ECM (the longest arrow corresponds to a length of 0.026543) and (b) ECM (the 
longest arrow corresponds to 1.21351)  
 
 
 
 
 
 
  
 
 
 
Figure 6: Effect of chemotaxis on tumor morphology for nutrient-poor microenvironment 
  
  
 
Figure 7: Effect of different chemotaxis coefficients on tumor growth and morphology for nutrient-poor 
microenvironment 
 
  
   
 
Figure 8: Tumor boundary for χE =1 in nutrient-rich environment at (a) 24 (b) t=36, (c) t=48 (d) t=52 and 
(e) nutrient and (f) net pressure contours at t=52 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 9: Tumor boundary for χE =1 and χS =50 in nutrient-rich environment at (a) t=40, (b) t=60, (c) t=80 
and (d) t= 100 
 
 
 
 
 
  
 
 
Figure 10: Effect of different extents of chemotaxis on tumor morphology for nutrient-rich 
microenvironment 
 
 
  
  
 
 
 
Figure 11: Effect of chemotaxis coefficient on tumor growth and morphology for nutrient-rich 
microenvironment (thick solid line for χE =1 and χS =0, dotted line for χE =0 and χS =10, dash-dotted line 
for χE =1 and χS =10, dashed line for χE =1 and χS =50, thin solid line χE =1 and χS =100) 
 
  
 
 
 
 
 
Figure 12: Effect of ECM degradation rate, λDE on tumor morphology with χE =1, χS =10, λM=100 and 
kS=1  
  
 
Figure 13: Effect of ECM degradation rate, λDE on tumor growth and morphology for χE =1, χS =10 and 
nutrient-rich (blue line) and nutrient-poor (N-P) (black line with * marker point) microenvironment.  
  
 
 
 
Figure 14: Effect of MDE production rate, λM on tumor morphology with χE =1, χS =10, λDE=0.01 and 
kS=1 
 
 
 
  
 
Figure 15: Effect of MDE production rate, λM on tumor growth and morphology for χE =1 and χS =10 for 
nutrient-rich (blue line) and nutrient-poor (N-P) (black line with * marker point) microenvironment.
  
 
 
 
 
  
 
  
 
 
 
Figure 16: Tumor boundary for low surface tension Γ= 0.01, χE =1 and χS =10 at (a) t=40 (b) t=60 and (c) 
t=80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 17: Tumor boundary for Γ= 0.01, χE =1 and χS =50 at (a) t=40 (b) t=60 and (c) t=80   
 
 
  
 
Figure 18: Effect of chemotaxis on tumor morphology for different surface tensions 
 
 
 
  
Figure 19: Tumor boundary for low proliferation case with χE =1 and χS =10 at (a) t=30 (b) t=45 (c) t=60, 
(d) t=75
  
  
 
Figure 20: Effect of chemotaxis coefficient on tumor growth and morphology for hypoxic low-proliferation 
environment (thick solid line for χE =1 and χS =0, dotted line for χE =0 and χS =10, dash-dotted line for χE 
=1 and χS =10, dashed line for χE =1 and χS =50, thin solid line χE =1 and χS =100) 
 
 
  
 
 
 
 
Figure 21: Tumor boundary for λP=0.1, χE =5 and χS =10 at (a) t=10, (b) t=20, (c) t=30 and (d) t=40 
 
 
 
 
 
  
 
 
Figure 22: Effect of chemotaxis on tumor shape for hypoxic low-proliferation microenvironment 
 
  
 
  
 
 
  
 
Figure 23: Effect of chemotaxis coefficient on tumor growth and morphology for hypoxic low-proliferation 
microenvironment (thick solid line for χE =5 and χS =0, dotted line for χE =0 and χS =10, dash-dotted line 
for χE =5 and χS =10, dashed line for χE =5 and χS =50, thin solid line χE =5 and χS =100) 
 
Table 1: List of Dimensionless Variables 
 
Dimensionless 
variable 
Symbol Unit 
Nutrient concentration 
r N
 
r N ¥
 
Intact ECM density 
r E
 
r E ¥
 
MDE density 
r M
 
r M 0  
Soluble ECM density 
r S
 
r E ¥
 
Cell velocity  L l p,max  
Pressure p  pT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: List of  Baseline Dimensionless Parameters 
 
 
Parameter Expression Significance Value Dimensional value 
MDE diffusion 
coefficient DM 
DM/(L2λP,max) MDE diffusion coefficient relative to 
 characteristic diffusivity L2/τ [1] 1 3.086X10-9 cm2/s 
MDE decay rate λDM λDM/λP,max MDE decay rate relative to maximum 
tumor-cell proliferation rate [1] 
10 15/day 
MDE tumor-cell 
Production rate λM λMρT /(λP,maxρM0) 
MDE production rate relative to 
maximum tumor-cell proliferation 
rate [1] 
100 
 
150/day 
ECM degradation 
rate λDE λDE/λP,max 
ECM degradation rate (by MDE) 
relative to maximum tumor-cell 
proliferation rate [1] 
0.01 
 
0.015/day 
Surface tension coefficient Γ G LpT  A measure of cell-cell and cell-ECM adhesion forces [2] 
0.05 
 
 
Rate of mitosis λP λP /λP,max Mitosis rate relative to maximum 
tumor-cell proliferation rate[1] 
1 1/1.5days 
Rate of apoptosis, λA λA/λP,max Apoptosis rate relative to tumor-cell 
 proliferation rate [3] 
0.1 (Low-nutrient) 
0.5 (High-nutrient) 
0.1/1.5days (Low-nutrient) 
0.5/1.5days (High-nutrient) 
Diffusion coefficient of 
soluble ECM 
DS/(L2λP,max) How fast soluble ECM diffuses in the 
length and time scale [4]  
1 
 
3.086X10-9 cm2/s 
Chemotaxis coefficient, χS 0 2
,max
S S
p
χ ρ
λ L  
The extent of chemotaxis of soluble 
ECM,  gradients 
10 
 
 
Haptotaxis coefficient, χE c E r E ¥
l p,maxL
2
 The extent of haptotaxis of intact 
ECM gradients [1] 
1 2600 cm2/s/M 
 Table 3: List of values 
 
 
 
 
Table 4: Effect of ECM degradation rate (λDE) on the time when  
the tumor shape parameter (S) is 1.5 
 
Taxis Coefficients λDE Low-nutrient Nutrient-rich 
χE =1, χS =0 0.01 33 58.5 
χE =1, χS =10 0.01 40 58.2 
χE =1, χS =10 0.1 22.5 20.9 
χE =1, χS =10 1 13.7 14.3 
χE =1, χS =10 10 58.2 84.7 
 
Table 5: Effect of MDE production rate (λM) on the time when  
the tumor shape parameter (S) is 1.5 
 
Taxis Coefficients λM Low-nutrient Nutrient-rich 
χE =1, χS =0 100 33 58.5 
χE =1, χS =10 10 46.5 84.8 
χE =1, χS =10 100 40 58.2 
χE =1, χS =10 1000 39.1 57 
 
 
 
Table 6: Parameter values used in section 4.4 
 
 
 
 
 
Parameter 
Low-nutrient 
(Section 4.1) 
High-nutrient 
(Section 4.2) 
Apoptosis rate 0.1 0.5 
Chemotaxis coefficient 10, 50 ,100 10, 50, 100, 500 
Chemotaxis coefficient, χS 10, 50 ,100 
Surface-tension coefficient, Γ  0.01 (low surface tension) 
0.05 (medium surface tension) 
  
Table 7: Parameter values used in section 4.5 
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Apoptosis rate 0 
Proliferation rate 0.1 
Haptotaxis coefficient 0, 1, 5 
Chemotaxis coefficient 0, 10, 50 ,100 
